Physician profile
Paul Capell
NPI 1083288617
$5,858.93
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $866 · 2022: $2,038 · 2023: $2,224 · 2024: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $756.67 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $753.64 | 2021-2024 | Caplyta |
| Abbvie INC. | $692.80 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $477.39 | 2021-2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| Janssen Pharmaceuticals, INC | $406.63 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $371.98 | 2021-2024 | Ingrezza |
| Indivior INC. | $369.36 | 2021-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $358.23 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Alkermes, INC. | $287.74 | 2021-2023 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $279.34 | 2021-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $228.72 | 2021-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $186.36 | 2022-2023 | Auvelity |
| Supernus Pharmaceuticals, INC. | $161.98 | 2021-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $136.83 | 2022-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $90.27 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $85.68 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.45 | 2021-2024 | Trintellix |
| Neuronetics, INC. | $28.83 | 2024 | Neurostar Tms Therapy System |
| Tempus Ai, INC | $21.67 | 2024 | |
| Bioxcel Therapeutics, INC. | $20.09 | 2023 | Igalmi |
| Eisai INC. | $19.76 | 2021 | |
| Owp Pharmaceuticals, INC. | $18.72 | 2023 | Lamotrigine, Subvenite |
| Neos Therapeutics, LP | $18.25 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.48 | 2022 | |
| Brainsway USA INC | $11.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Capell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.